Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: Activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome

Endocrine-Related Cancer

Volumn 11, Issue 4, 2004, Pages 897-911

  Eisenhofer, G ^a   Huynh, T T ^a   Pacak, K ^b   Brouwers, F M ^b   Walther, M M ^c   Linehan, W M ^c   Munson, P J ^d   Mannelli, M ^e   Goldstein, D S ^a   Elkahloun, A G ^f,g  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF FLORENCE   (Italy)

^f NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANGIOPOIETIN 1; CADHERIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYSTEINE RICH PROTEIN 61; GLUCOSE TRANSPORTER; HYPOCALCIN; INTERSTITIAL COLLAGENASE; NEUROPILIN 1; NORADRENALIN; PLACENTAL GROWTH FACTOR; TENASCIN; TIE 1 RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE TUMOR; FAMILIAL CANCER; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; PHENOTYPE; PHEOCHROMOCYTOMA; SIPPLE SYNDROME; UPREGULATION; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHILD; EPINEPHRINE; FEMALE; GENE EXPRESSION PROFILING; HIPPEL-LINDAU DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NOREPINEPHRINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHEOCHROMOCYTOMA;

EID: 19944429270     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00838     Document Type: Article

References (78)

1. Abe M & Sato Y 2001 cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 4 289-298.
2. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W & Klein R 1999 Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes and Development 13 295-306.
3. Allander SV, Nupponen NN, Ringner M, Hostetter G, Maher GW, Goldberger N, Chen Y, Carpten J, Elkahloun AG & Meltzer PS 2001 Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Research 61 8624-8628.
4. Bautch VL, Redick SD, Scalia A, Harmaty M, Carmeliet P & Rapoport R 2000 Characterization of the vasculogenic block in the absence of vascular endothelial growth factor-A. Blood 95 1979-1987.
5. Benjamini Y & Hochberg Y 1995 Controlling false discovery rate: a practical and powerfull approach to multiple testing. Journal of the Royal Statistical Society 57 289-300.
6. Brigstock DR 2002 Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 5 153-165.
7. Bruick RK & McKnight SL 2001 A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 1337-1340.
8. Bryant J, Farmer J, Kessler LJ, Townsend RR & Nathanson KL 2003 Pheochromocytoma: the expanding genetic differential diagnosis. Journal of the National Cancer Institute 95 1196-1204.
9. Calnek DS & Grinnell BW 1998 Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Experimental Cell Research 238 294-298.
10. Cao G, O'Brien CD, Zhou Z, Sanders SM, Greenbaum JN, Makrigiannakis A & DeLisser HM 2002 Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. American Journal of Physiology and Cellular Physiology 282 C1181-C1190.
11. Cha HJ, Jeong MJ & Kleinman HK 2003 Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute 95 1674-1680.
12. Chen CC, Mo FE & Lau LF 2001 The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts. Journal of Biological Chemistry 276 47329-47337.
13. Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS & Trent JM 2002 Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics 18 1207-1215.
14. Cioffi CL, Liu XQ, Kosinski PA, Garay M & Bowen BR 2003 Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochemical and Biophysical Research Communications 303 947-953.
15. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ & Mäher ER 2001 Contrasting effects on HIF-lalpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Human Molecular Genetics 10 1029-1038.
16. Davidowitz EJ, Schoenfeld AR & Burk RD 2001 VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Molecular and Cellular Biology 21 865-874.
17. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA & Trent JM 1996 Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics 14 457-460.
18. Dluhy RG 2002 Screening for genetic causes of hypertension. Current Hypertension Reports 4 439-444.
19. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL & Kopin IJ 1986 Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clinical Chemistry 32 2030-2033.
20. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW & Pacak K 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Journal of Clinical Endocrinology and Metabolism 86 1999-2008.
21. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G & Flamme I 2003 Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (FIk-1). Journal of Biological Chemistry 278 7520-7530.
22. Esteban-Barragan MA, Avila P, Alvarez-Tejado M, Gutierrez MD, Garcia-Pardo A, Sanchez-Madrid F & Landazuri MO 2002 Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Research 62 2929-2936.
23. Favier J, Kempf H, Corvol P & Gasc JM 1999 Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase. FEBS Letters 462 19-24.
24. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD & Semenza GL 1996 Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 16 4604-4613.
25. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD & Lander ES 1999 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 531-537.
26. Grant DS, Rose W, Yaen C, Goldstein A, Martinez J & Kleinman H 1999 Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis 3 125-135.
27. van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH & Boomsma F 2002 The value of plasma markers for the clinical behaviour of phaeochromocytomas. European Journal of Endocrinology 147 85-94.
28. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E & Okada Y 2002 Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. Journal of Biological Chemistry 277 36288-36295.
29. Henry MD, Satz JS, Brakebusch C, Costell M, Gustafsson E, Fassler R & Campbell KP 2001 Distinct roles for dystroglycan, beta1 integrin and perlecan in cell surface laminin organization. Journal of Cell Science 114 1137-1144.
30. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M & Kaelin WG Jr 2001 von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Molecular Genetics 10 1019-1027.
31. Humtsoe JO, Feng S, Thakker GD, Yang J, Hong J & Wary KK 2003 Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP. EMBO Journal 22 1539-1554.
32. Ignatius MJ, Large TH, Houde M, Tawil JW, Barton A, Esch F, Carbonetto S & Reichardt LF 1990 Molecular cloning of the rat integrin alpha 1-subunit: a receptor for laminin and collagen. Journal of Cellular Biology 111 709-720.
33. Iino S, Kobayashi S & Hidaka H 1997 Heterogeneous distribution of neurocalcin-immunoreactive nerve terminals in the mouse adrenal medulla. Cell and Tissue Research 289 439-444.
34. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr & Goldberg MA 1996 Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. PNAS 93 10595-10599.
35. Jiang X & Couchman JR 2003 Perlecan and tumor angiogenesis. Journal of Histochemistry and Cytochemistry 51 1393-1410.
36. John H, Ziegler WH, Hauri D & Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology 53 679-683.
37. Kees UR, Ford J, Watson M, Murch A, Ringner M, Walker RL & Meltzer P 2003 Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease. Molecular Cancer Therapeutics 2 671-677.
38. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM & Meltzer PS 1998 Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Research 58 5009-5013.
39. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS & Koh GY 2001 Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. Journal of Biological Chemistry 276 7614-7620.
40. Kimura N, Sasano N, Miura Y & Kobayashi K 1984 Adrenal and extra-adrenal pheochromocytomas: an ultrastructural and formaldehyde-induced fluorescence study with catecholamine content. Tohoku Journal of Experimental Medicine 142 1-14.
41. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J & Sato H 2001 Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line. Cancer Research 61 7985-7991.
42. Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, Pacak K, Chrousos GP, Zhuang Z & Lubensky IA 2002 Pheochromocytoma in von Hippel-Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocrine Pathology 13 17-27.
43. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T & Ushio Y 2001 Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Research 61 6248-6254.
44. Lafuente JV, Adan B, Alkiza K, Garibi JM, Rossi M & Cruz-Sanchez FF 1999 Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. Journal of Molecular Neuroscience 13 177-185.
45. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ & Riggins GJ 2001 Transcriptional response to hypoxia in human tumors. Journal of the National Cancer Institute 93 1337-1343.
46. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA & Charles ST 1998 Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvascular Research 55 29-42.
47. Lantuejoul S, Constantin B, Drabkin H, Brambilla C, Roche J & Brambilla E 2003 Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. Journal of Pathology 200 336-347.
48. Lelievre E, Mattot V, Huber P, Vandenbunder B & Soncin F 2000 ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. Oncogene 19 2438-2446.
49. Lindner V, Booth C, Prudovsky I, Small D, Maciag T & Liaw L 2001 Members of the Jagged/Notch gene families are expressed in injured arteries and regulate cell phenotype via alterations in cell matrix and cell-cell interaction. American Journal of Pathology 159 875-883.
50. Liu D, Jia H, Holmes DI, Stannard A & Zachary I 2003 Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arteriosclerosis, Thrombosis and Vascular Biology 23 2002-2007.
51. Luque A, Carpizo DR & Iruela-Arispe ML 2003 ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. Journal of Biological Chemistry 278 23656-23665.
52. McCarthy MJ, Crowther M, Bell PR & Brindle NP 1998 The endothelial receptor tyrosine kinase tie-1 is up-regulated by hypoxia and vascular endothelial growth factor. FEBS Letters 423 334-338.
53. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM & Klausner RD 2002 The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 247-255.
54. Mathupala SP, Rempel A & Pedersen PL 2001 Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. Journal of Biological Chemistry 276 43407-43412.
55. Murphy JF & Fitzgerald DJ 2001 Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. FASEB Journal 15 1667-1669.
56. Neufeld G, Cohen T, Gengrinovitch S & Poltorak Z 1999 Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 13 9-22.
57. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M & Szmigielski C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 346 1459-1466.
58. Nikitenko LL, Smith DM, Bicknell R & Rees MC 2003 Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB Journal 17 1499-1501.
59. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K & Sato Y 2001 Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochemical and Biophysical Research Communications 289 39-43.
60. Ponce ML, Nomizu M & Kleinman HK 2001 An angiogenic laminin site and its antagonist bind through the alpha(v)beta3 and alpha5beta1 integrins. FASEB Journal 15 1389-1397.
61. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A & Anand-Apte B 2003 A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine 9 407-415.
62. Reisdorff J, En-Nia A, Stefanidis I, Floege J, Lovett DH & Mertens PR 2002 Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. Journal of the American Society of Nephrology 13 1568-1578.
63. Schweda F, Blumberg FC, Schweda A, Nabel C, Holmer SR, Riegger GA, Pfeifer M & Kramer BK 2000 Effects of chronic hypoxia on renal PDGF-A, PDGF-B, and VEGF gene expression in rats. Nephron 86 161-166.
64. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP & Detmar M 1997 Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. PNAS 94 13612-13617.
65. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR & Detmar M 2002 The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. American Journal of Pathology 160 195-204.
66. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA & Iozzo RV 1998 Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. Journal of Clinical Investigation 102 1599-1608.
67. Soker S, Svahn CM & Neufeld G 1993 Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. Journal of Biological Chemistry 268 7685-7691.
68. Sowter HM, Raval R, Moore J, Ratcliffe PJ & Harris AL 2003 Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Research 63 6130-6134.
69. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP & King GL 2000 Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. Journal of Biological Chemistry 275 40725-40731.
70. Teruyama K, Abe M, Nakano T, Takahashi S, Yamada S & Sato Y 2001 Neurophilin-1 is a downstream target of transcription factor Ets-1 in human umbilical vein endothelial cells. FEBS Letters 504 1-4.
71. Tian H, Hammer RE, Matsumoto AM, Russell DW & McKnight SL 1998 The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes and Development 12 3320-3324.
72. Van Limpt VA, Chan AJ, Van Sluis PG, Caron HN, Van Noesel CJ & Versteeg R 2003 High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type. International Journal of Cancer 105 61-69.
73. Wang L, Zeng H, Wang P, Soker S & Mukhopadhyay D 2003 Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-dependent endothelial cell migration. Journal of Biological Chemistry 278 48848-48860.
74. Wary KK, Thakker GD, Humtsoe JO & Yang J 2003 Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Molecular Cancer 2 25.
75. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH & Eckardt KU 2003 Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB Journal 17 271-273.
76. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH, Gregory RJ & Jiang C 2003 Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circulation Research 93 664-673.
77. Yang YS, Song HD, Peng YD, Huang QH, Li RY, Zhu ZD, Hu RM, Han ZG & Chen JL 2003 The gene expression profiling of sporadic pheochromocytoma and novel full-length cDNAs cloning. Endocrine-Related Cancer 10 621-627.
78. van der Zwaag B, Hellemons AJ, Leenders WP, Burbach JP, Brunner HG, Padberg GW & Van Bokhoven H 2002 PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis. Developmental Dynamics 225 336-343.